Literature DB >> 19104790

An analysis of the clinical development of drugs in Norway for the year 2000: the completion of research and publication of results.

Ola P Hole1, Sigurd Nitter-Hauge, Henrik R Cederkvist, Finn O Winther.   

Abstract

OBJECTIVE: In Norway, very little data are available on the relation between the total number of research projects on the clinical development of drugs that have been started, the number of these projects in which the research phase has been completed and the number of projects for which results have been published. The aim of this study was to determine the number of projects in which the research phase had been completed and the results published.
MATERIAL AND METHODS: Information on research projects carried out on the clinical development of drugs during the year 2000 was obtained from the archives of the Norwegian Research Ethical Committee (REC) and subsequently analysed.
RESULTS: The final analysis revealed that 245 research projects on the clinical development of drugs had been started in 2000. Of these, 178 (73%) completed the research phase as planned. The results of 131 (54%) of these projects were published in a scientific journal, and another 34 (14%) were reported as a congress abstract or as report to a sponsor; 80 (33%) were not published at all. Industrial sponsors seemed to promote both the completion of the research process and the publication of results in scientific journals.

Mesh:

Year:  2008        PMID: 19104790     DOI: 10.1007/s00228-008-0601-8

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  4 in total

1.  Clinical research: the influence of the pharmaceutical industry.

Authors:  O P Hole; F O Winther; B Straume
Journal:  Eur J Clin Pharmacol       Date:  2001 Jan-Feb       Impact factor: 2.953

2.  [Clinical trials in Norway--completion and reporting are not satisfactory].

Authors:  Linda Sandaker; Bente Fjeld; Asmund Reikvam; Harald Lislevand; Steinar Madsen
Journal:  Tidsskr Nor Laegeforen       Date:  2004-11-18

3.  An analysis of the clinical development of drugs in Norway for the years 2000 and 2004: the influence of the pharmaceutical industry.

Authors:  Finn O Winther; Ola P Hole; Sigurd Nitter-Hauge
Journal:  Eur J Clin Pharmacol       Date:  2007-08-03       Impact factor: 2.953

4.  Scientific quality of clinical research. An analysis of 40 research projects in pharmacology/pharmacotherapy.

Authors:  F O Winther; O P Hole
Journal:  Eur J Clin Pharmacol       Date:  1997       Impact factor: 2.953

  4 in total
  4 in total

Review 1.  The financing of drug trials by pharmaceutical companies and its consequences: part 2: a qualitative, systematic review of the literature on possible influences on authorship, access to trial data, and trial registration and publication.

Authors:  Gisela Schott; Henry Pachl; Ulrich Limbach; Ursula Gundert-Remy; Klaus Lieb; Wolf-Dieter Ludwig
Journal:  Dtsch Arztebl Int       Date:  2010-04-30       Impact factor: 5.594

2.  Occurrence and determinants of selective reporting of clinical drug trials: design of an inception cohort study.

Authors:  Cornelis A van den Bogert; Patrick C Souverein; Cecile T M Brekelmans; Susan W J Janssen; Manon van Hunnik; Gerard H Koëter; Hubertus G M Leufkens; Lex M Bouter
Journal:  BMJ Open       Date:  2015-07-07       Impact factor: 2.692

3.  Non-Publication Is Common among Phase 1, Single-Center, Not Prospectively Registered, or Early Terminated Clinical Drug Trials.

Authors:  Cornelis A van den Bogert; Patrick C Souverein; Cecile T M Brekelmans; Susan W J Janssen; Gerard H Koëter; Hubert G M Leufkens; Lex M Bouter
Journal:  PLoS One       Date:  2016-12-14       Impact factor: 3.240

4.  Barriers towards the publication of academic drug trials. Follow-up of trials approved by the Danish Medicines Agency.

Authors:  Louise Berendt; Lene Grejs Petersen; Karin Friis Bach; Henrik Enghusen Poulsen; Kim Dalhoff
Journal:  PLoS One       Date:  2017-05-09       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.